title: Cerebral adenosine triphosphate-sensitive K+ channels may be impaired during acute cerebral ischemia in spontaneously hypertensive rats.
abstract: To elucidate the role of cerebral adenosine triphosphate (ATP)-sensitive K+ channels (KATP) on arterial pressure regulation during acute cerebral ischemia in spontaneously hypertensive rats (SHR), intracerebroventricular (i.c.v.) injections of either glibenclamide, a specific blocker of KATP, or pinacidil, a KATP opener, were performed in SHR and Wistar-Kyoto rats (WKY). Intracerebroventricular injections of glibenclamide elicited a vasopressor response in WKY with bilateral ligation of the carotid arteries, whereas the response was smaller in SHR. It increased plasma AVP, but decreased pituitary AVP in WKY with ligation, but not in SHR. Systemic administration of an AVP V1 receptor antagonist, OPC-21268, abolished the vasopressor responses to i.c.v. injections of glibenclamide in WKY. Bilateral ligation of the carotid arteries augmented the vasodepressor responses to i.c.v. injections of pinacidil in WKY, but not in SHR. Cerebral KATP may play a role in buffering a rise in arterial pressure by inhibiting the release of AVP from the pituitary glands during acute cerebral ischemia in WKY, but this mechanism might be deranged in SHR, probably due to impaired responsiveness of cerebral KATP to ischemia.
authors: Department of Clinical Laboratory and Medicine, Kyoto Prefectural University of Medicine, Japan.
authors: M
authors: M
authors: Nishimura
authors: H
authors: H
authors: Takahashi
authors: A
authors: A
authors: Nanbu
authors: M
authors: M
authors: Sakamoto
authors: T
authors: T
authors: Nakanishi
authors: M
authors: M
authors: Yoshimura
mesh_terms: D000255:Adenosine Triphosphate / Q000502:physiology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D000959:Antihypertensive Agents / Q000494:pharmacology; D001127:Arginine Vasopressin / Q000032:analysis / Q000097:blood; D001157:Arterial Occlusive Diseases / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002545:Brain Ischemia / Q000503:physiopathology*; D002339:Carotid Arteries / Q000503:physiopathology; D002540:Cerebral Cortex / Q000098:blood supply / Q000737:chemistry*; D005905:Glyburide / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D006973:Hypertension / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008026:Ligation; D008297:Male; D020110:Pinacidil; D010880:Piperidines / Q000494:pharmacology; D015221:Potassium Channels / Q000502:physiology*; D015363:Quinolones / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR / Q000502:physiology*; D011921:Rats, Inbred WKY
chemical_list: D000317:Adrenergic alpha-Antagonists; D065092:Antidiuretic Hormone Receptor Antagonists; D000959:Antihypertensive Agents; D006146:Guanidines; D007004:Hypoglycemic Agents; D010880:Piperidines; D015221:Potassium Channels; D015363:Quinolones; D001127:Arginine Vasopressin; C068644:OPC 21268; D020110:Pinacidil; D000255:Adenosine Triphosphate; D005905:Glyburide